FDA Warning to Amgen’s Tavneos: Understanding the Risks and Precautions

Author : Shruti Sinha | Published On : 01 Apr 2026

The FDA Warning to Amgen’s Tavneos has raised awareness about potential liver-related risks associated with this vasculitis drug. Tavneos (avacopan) is used in the treatment of autoimmune conditions, but recent safety findings have linked it to serious liver injury.

Healthcare providers are advised to monitor liver function regularly in patients using Tavneos. Warning signs such as jaundice, fatigue, and abdominal discomfort should be taken seriously and addressed promptly.

This FDA Warning to Amgen’s Tavneos highlights the importance of pharmacovigilance and continuous monitoring of medications after they reach the market. Proper evaluation of risks and benefits is essential when considering treatment options.

Patients are encouraged to stay informed and communicate openly with their healthcare providers about any symptoms. Understanding updates like the FDA Warning to Amgen’s Tavneos can support safer treatment decisions and improve overall patient care.